Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spermatogenesis and centriole-associated protein 1 (SPATC1), also known as speriolin, is a centrosome-associated protein specifically expressed in spermatogenic cells[1][2][3]. It enables gamma-tubulin binding activity and localizes to the centrosome, where it is implicated in organizing and stabilizing centrosome structure during spermatogenesis, particularly in round spermatids and mature sperm[1][2][3]. SPATC1 interacts with the mitotic regulator Cdc20 and is thought to contribute to the faithful inheritance and assembly of centrioles during spermatogenesis and potentially during early zygote development[1][2]. Current evidence suggests SPATC1 plays a specialized role in male germ cell development but it is not a known therapeutic target and there is no evidence for its involvement as a biomarker, drug target, or in disease pathogenesis, although disruption could hypothetically impact male fertility[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spermatogenesis and centriole-associated protein 1 (SPATC1).